Search academic texts

Information × Registration Number 2122U005384, Article popup.category Thesis Title popup.author popup.publication 01-01-2022 popup.source_user Сумський державний університет popup.source https://essuir.sumdu.edu.ua/handle/123456789/87802 popup.publisher Elsevier Description IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim DFS analysis, the significance boundary was crossed for the stage II-IIIA PD-L1 TC 1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), with greatest benefit in the PD-L1 TC 50% subgroup (unstratified HR, 0.43; 95% CI: 0.27, 0.68). Here we present further analyses in PD-L1 TC 50% stage II-IIIA NSCLC pts. popup.nrat_date 2025-05-12 Close